Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SneezeEze is an intranasal powder spray formulation composed of inert hydroxypropyl methylcellulose (HPMC) used for the mechanical prevention of allergic rhinitis. Upon insufflation, the cellulose powder reacts with the moisture of the nasal mucosa to form a clear, mucoadhesive gel barrier. This physical layer effectively traps airborne allergens such as pollen, dust mites, and pet dander, preventing their contact with the nasal lining and subsequent activation of the inflammatory cascade. Because it is non-systemic and pharmacologically inert, it is frequently used as a drug-free alternative or adjunct therapy for hay fever and other respiratory allergies, particularly in populations where systemic antihistamines or corticosteroids may be contraindicated, such as in pediatric or pregnant patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SneezeEze.